{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T05:24:53.001631+00:00","company":{"ticker":"TOVX","cik":894158,"company_name":"Theriva Biologics, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"462832afab8182407513e2f6c88570c27eb3972f","cik":894158,"ticker":"TOVX","company_name":"Theriva Biologics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Theriva Biologics, Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Theriva Biologics, Inc., a Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended March 31, 2026.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001104659-26-055679","anchor_url":"https://secwatch.observer/filing/0001104659-26-055679#claim-462832afab8182407513e2f6c88570c27eb3972f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926055679/0001104659-26-055679-index.htm"},{"fact_type":"material_agreement","fact_key":"24ac7b0ff5b87062ba719e7090696a20cbd26803","cik":894158,"ticker":"TOVX","company_name":"Theriva Biologics, Inc.","filed_at":"2026-02-18T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"license","counterparty":"Rasayana Therapeutics, Inc.","effective_date":"2026-02-18","item_codes_triggered":["1.01"],"value_text":"$300,000"},"claim":"Theriva Biologics, Inc. entered into Agreement with Rasayana Therapeutics, Inc. valued at $300,000 (effective 2026-02-18).","evidence_excerpt":"On February 18, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into a license agreement (the “Agreement”) with Rasayana Therapeutics, Inc. (“Rasayana”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-016792","anchor_url":"https://secwatch.observer/filing/0001104659-26-016792#claim-24ac7b0ff5b87062ba719e7090696a20cbd26803","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926016792/0001104659-26-016792-index.htm"},{"fact_type":"restructuring_charge","fact_key":"4c62e1e733757f342ca395801422ff8bd8df458e","cik":894158,"ticker":"TOVX","company_name":"Theriva Biologics, Inc.","filed_at":"2025-10-02T23:59:59+00:00","payload":{"affected_area":"global Company workforce","charge_text":"approximately $520,000","effective_date":"2025-09-30","event_type":"restructuring","headcount_text":"approximately seven employees or 32% of the current global Company workforce","item_codes_triggered":["2.05"]},"claim":"Theriva Biologics, Inc. announced a restructuring with charges of approximately $520,000 affecting global Company workforce (approximately seven employees or 32% of the current global Company workforce).","evidence_excerpt":"its best opportunity for success. The\nCompany expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately\n$520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025.\nThese charges consist primarily of cash severance and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-096047","anchor_url":"https://secwatch.observer/filing/0001104659-25-096047#claim-4c62e1e733757f342ca395801422ff8bd8df458e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465925096047/0001104659-25-096047-index.htm"},{"fact_type":"earnings_release","fact_key":"2ed7db578632d6d58226dd559e8aa6939bc7aca9","cik":894158,"ticker":"TOVX","company_name":"Theriva Biologics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":null},"claim":"Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-057689","anchor_url":"https://secwatch.observer/filing/0001104659-24-057689#claim-2ed7db578632d6d58226dd559e8aa6939bc7aca9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm"}]}